SCHEMBL8314060

SCHEMBL8314060

c1ccc(-c2cnc3[nH]cc(-c4ccoc4)c3c2)nc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 3/20 0.73
CDK2 P24941 4/20 0.58
CCNT1 O60563 2/20 0.58
CCNA2 P20248 2/20 0.58
CDK9 P50750 2/20 0.58
AXL P30530 5/20 0.52
TNIK Q9UKE5 1/20 0.52
IGF1R P08069 2/20 0.47
IMPDH2 P12268 1/20 0.47
NTRK1 P04629 2/20 0.45
PLK4 O00444 2/20 0.45
AURKA O14965 2/20 0.45
ROCK2 O75116 2/20 0.45
PRKD3 O94806 2/20 0.45
INSR P06213 2/20 0.45
CDK1 P06493 2/20 0.45
FES P07332 2/20 0.45
ROS1 P08922 2/20 0.45
FGFR1 P11362 2/20 0.45
PHKG2 P15735 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13745464 0.85 CDK8 (1.00) CDK8CDK2CCNT1CCNA2CDK9
SCHEMBL8320115 0.84 CDK8 (0.84) CDK8CDK2CCNT1CCNA2CDK9
SCHEMBL8313417 0.83 CDK8 (0.73) CDK8CDK2CCNT1CCNA2CDK9
SCHEMBL8324861 0.82 CDK8 (0.85) CDK8CDK2CCNT1CCNA2CDK9
SCHEMBL12763457 0.81 CDK8 (0.79) CDK8CDK2CCNT1CCNA2CDK9
SCHEMBL13745492 0.81 CDK8 (0.73) CDK8CDK2CCNT1CCNA2CDK9
SCHEMBL8324926 0.81 CDK8 (0.73) CDK8CDK2CCNT1CCNA2CDK9
SCHEMBL8314540 0.81 CDK8 (0.73) CDK8CDK2CCNT1CCNA2CDK9
SCHEMBL8320981 0.81 CDK8 (0.73) CDK8CDK2CCNT1CCNA2CDK9
SCHEMBL12763453 0.81 CDK8 (0.77) CDK8CDK2CCNT1CCNA2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 CDK8 360/4885CDK2 153/4885CCNT1 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.